Human pluripotent stem cell endothelial-cell differentiation

• Use a validated hPSC line maintained under pluripotency conditions before differentiation, because the cited protocols begin with human ESCs or iPSCs and convert them into endothelial progenitors or endothelial cells.

• Use CHIR99021 or another GSK3 inhibitor for early WNT activation, because multiple protocols use GSK3 inhibition to induce mesodermal or vascular progenitor stages.

• Use BMP4, VEGF-A, bFGF/FGF2, cAMP-related stimulation, DAPT/Notch inhibition, or defined growth-factor-free medium only in combinations explicitly matching the selected protocol, because these factors were reported in different validated endothelial differentiation schemes.

• Use antibodies against CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, ICAM-1, or CD14/CD45 exclusion markers for flow cytometry, sorting, or immunostaining according to the endpoint being measured.

• Use acetylated LDL uptake assays and tube/network-formation assays to assess endothelial functional phenotype after marker acquisition.

• Use standard hPSC culture equipment, a CO₂ incubator, biosafety cabinet, centrifuge, fluorescence microscope, flow cytometer or cell sorter, and imaging system for cell culture, marker quantification, endothelial enrichment, and functional readouts.

• Use Matrigel or comparable matrix-based angiogenesis assay equipment only for functional tube/network testing, because this readout was reported in several differentiation studies.

• Start with healthy, undifferentiated hPSCs suitable for monolayer differentiation, because the cited methods use adherent feeder-free or serum-free/defined formats to reduce embryoid-body heterogeneity and support reproducible vascular induction.

• Prepare the exact differentiation medium according to one selected literature protocol rather than mixing protocols;
• Common validated designs include WNT/GSK3 inhibition followed by defined culture, VEGF-A exposure, BMP4 plus VEGF-A, VEGF plus cAMP, or VEGF plus Notch inhibition.

• Induce early mesoderm or vascular progenitor commitment by exposing hPSCs to a GSK3 inhibitor/CHIR99021 during the first differentiation stage;
• Published protocols report 24 hours to several days of WNT/GSK3 modulation before endothelial specification.

• Continue differentiation toward endothelial progenitors or endothelial cells using the second-stage conditions reported in the chosen paper, such as VEGF-A, BMP4, bFGF/FGF2, cAMP-related stimulation, Notch inhibition, or defined growth-factor-free culture.

• Assess endothelial progenitor emergence around day 5-6 when using rapid WNT-based or VEGF/BMP4-based protocols, because several studies report CD34⁺CD31⁺, VE-cadherin⁺CD31⁺, or KDR-high endothelial progenitor populations within this window.

• Continue endothelial maturation or expansion only under conditions reported in the selected paper, because studies differ in whether they purify CD34⁺/CD31⁺/VE-cadherin⁺ cells, passage endothelial cells, or continue serum-free maturation.

• Quantify differentiation by flow cytometry or immunostaining for CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, and non-endothelial exclusion markers such as CD14 or CD45 when reported.

• Confirm function using acetylated LDL uptake, tube/network formation, endothelial barrier assays, nitric oxide production, or in vivo vascular incorporation only when these assays match the study objective and available facility approvals.

• Use undifferentiated hPSCs as a negative control for endothelial markers, and use mature endothelial cells such as HUVECs or protocol-derived purified endothelial cells as comparator controls when the cited study used them for phenotype or function benchmarking.

• Report biological replicates, cell line identity, sex of hPSC lines where relevant, passage/enrichment status, marker percentages, and functional assay outcomes, because differentiation efficiency can vary by line and sex-dependent VEGF expression has been reported.

Low CD31⁺CD34⁺ or VE-cadherin⁺ endothelial yield:

Possible cause
Insufficient early WNT/GSK3-driven mesoderm induction or mismatch between early induction and later endothelial specification.
Solution
Use a complete validated staged protocol rather than partial factor substitution, because WNT/GSK3 inhibition followed by defined endothelial specification is repeatedly associated with endothelial progenitor generation.

Female hPSC lines show weaker endothelial progenitor differentiation in a GSK3-inhibitor-based protocol:

Possible cause
Sex-dependent differences in endogenous VEGF expression.
Solution
Add VEGF during the second stage when following the relevant GSK3-inhibitor endothelial progenitor protocol, because VEGF improved female hPSC endothelial progenitor differentiation in that study.

Cells express endothelial markers but show low vWF production or immature round Weibel-Palade bodies:

Possible cause
That hiPSC-derived endothelial cells can retain an immature endothelial phenotype.
Solution
Do not assume that pericyte co-culture, flow, HDAC inhibitors, or altered factor timing will reliably mature the cells, because these approaches did not substantially improve maturation in the cited study; extended culture beyond 30 days showed more mature WPB features but with low cell numbers and deterioration.

Endothelial differentiation decreases after pathway inhibition during specification:

Possible cause
That MAPK and PI3K signaling are required for efficient endothelial differentiation in the cited protocol.
Solution
Avoid adding MAPK or PI3K inhibitors unless the experiment is specifically designed to test pathway dependence.